Expression Changes Of C-erbB-2, CXCR4 And ER-α After Neoadjuvant Chemotherapy In Breast Cancer And Their Significance

Objective To study includes: C-erbB-2, CXCR4 and ER-αwere measured by immunohistochemistry on neoadjuvant therapy to breast cancer influence and the possible function mechanism. Methods 48 patient with breast cancer were measured using needle core biopsy in prechemotherapy and postchemotherapy(at the time of surgery) tumor specimens .The relationship between change expression of CerbB-2, CXCR4 in specimen with pathological change were compared. Results Analyzed by immunohistochemistry (IHC) on full tissue sections , C-erbB-2 and CXCR4 level was down-regulated after the neoadjuvantchemotherapy on full tissue sections. Change expression of CerbB-2 and CXCR4 in specimen tended to be correlated with pathological change to the neoadjuvant chemotherapy on full tissue sections. No correlation was observed change expression of ER-αin specimen with pathological response to the neoadjuvant chemotherapy. Conclusion A significant correlation between pretreatment levels of CerbB-2 and those of CXCR4 were observed. our results suggested that after treated with neoadjuvant systemic therapy, the cerbB-2, ER-αand CXCR4 were decreaced expression. these objective marker may be useful in evaluating the clinical response of neoadjuvantchemotherapy and selecting chemotherapy regimen for postoperative chemotherapy in breast cancer.